Skip to main content

Renovacor, Inc. (RCOR)

NYSEAMERICAN: RCOR · IEX Real-Time Price · USD
8.12
0.00 (0.00%)
After-hours:Oct 15, 2021 8:00 PM EDT
8.12
0.06 (0.77%)
At close: Oct 15, 4:00 PM
Market Cap136.10M
Revenue (ttm)n/a
Net Income (ttm)-2.62M
Shares Out1.94M
EPS (ttm)-4.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,596
Open8.53
Previous Close8.06
Day's Range7.95 - 8.53
52-Week Range7.58 - 11.12
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About RCOR

Renovacor, Inc., an early-stage biotechnology company, engages in developing a pipeline of adeno-associated virus (AAV) based gene therapies for Bcl2-associated athanogene 3 (BAG3) associated diseases. Its lead program is recombinant AAV-based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the BAG3 gene; and REN-001, an AAV9-based gene therapy to treat BAG3-associated DCM. The company was incorporated in 2013 and is based in Greenwich, Connecticut.

IndustryBiotechnology
Founded2013
Employees2
Stock ExchangeNYSEAMERICAN
Ticker SymbolRCOR
Full Company Profile

Financial Performance

Financial Statements

News

Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on...

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. Closes its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange.

1 month ago - Business Wire

Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announ...

1 month ago - PRNewsWire

Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific ...

NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular an...

1 month ago - PRNewsWire

Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality A...

Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy Dr. Zhang has over 20 years of experience in regulatory affairs, wi...

3 months ago - GlobeNewsWire

Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F.

Appointments to be effective upon closing of the previously announced merger between Renovacor and Chardan Healthcare Acquisition 2 Corp. Appointments to be effective upon closing of the previously anno...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chardan Healthcare Acquisition 2 Corp. - ...

NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...

6 months ago - PRNewsWire

Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.

PHILADELPHIA and NEW YORK, March 23, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor" or the "Company"), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiov...

6 months ago - PRNewsWire